Citius Oncology, Inc. (CTOR)

Over the past six months, Citius Oncology secured $9.0 million in gross proceeds through a registered direct offering and concurrent private placement in July 2025, and also secured $12.5 million in financing during fiscal Q3 2025. The company finalized an exclusive Master Service Agreement with EVERSANA and signed a U.S. distribution services agreement with McKesson in October 2025, and entered into a distribution services agreement with Cardinal Health in June 2025, to support LYMPHIR's commercialization. LYMPHIR was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology in September 2024. The company announced the deployment of a proprietary AI platform and deeper collaboration with Verix in November 2025. Citius Oncology reported its fiscal Q3 2025 results, showing a net loss of $5.4 million ($0.08 per share). The company is scheduled to exhibit at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in December 2025 to present LYMPHIR. As of November 26, 2025, the stock price was $1.26, showing a 42.37% increase over the last year, but a -27.17% decrease over the last month.

Information directly addressing the demand seasonality for Citius Oncology, Inc.'s products and services, specifically LYMPHIR, is not explicitly available. Demand would likely be driven by medical need, physician adoption, and reimbursement rather than traditional seasonal consumer patterns. The demand for specialized oncology therapies typically remains relatively stable throughout the year, dictated by disease incidence and progression, rather than fluctuating with seasons.

Citius Oncology, Inc. (CTOR) is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies. It operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry, and is a subsidiary of Citius Pharmaceuticals, Inc. Their main product is LYMPHIR (denileukin diftitox-cxdl), an FDA-approved immunotherapy for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL).

Citius Oncology, Inc. is headquartered in Cranford, New Jersey, United States. The company's primary focus for commercialization of LYMPHIR is the U.S. market, with distribution agreements in place with major pharmaceutical wholesalers like McKesson and Cardinal Health to support its planned U.S. commercial launch in Q4 2025. Citius Oncology has also established international access to LYMPHIR through named patient programs in Southern Europe.

Citius Oncology's brand reputation has been positively influenced by the FDA approval of LYMPHIR and strategic agreements with major distributors and commercialization partners. The integration of AI platforms also contributes to a perception of innovation. The company's history of net losses could be a point of concern, but recent news focuses on the positive advancements related to LYMPHIR's launch.

The ownership structure of Citius Oncology (CTOR) stock includes institutional investors (0.03% to 0.18%), insiders (7.33%), and public companies and individual investors (92.49%). Major institutional owners and shareholders include Armistice Capital, Llc, Vanguard Group Inc, and Geode Capital Management, Llc. Leonard Mazur, the CEO, owns the most shares of Citius Oncology (CTOR) among individual investors.